56R0 Stock Overview
Through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
NanoVibronix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.46 |
| 52 Week High | US$1.21 |
| 52 Week Low | US$0.43 |
| Beta | 1.51 |
| 11 Month Change | -5.37% |
| 3 Month Change | -11.07% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 56R0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | 0.2% |
| 1Y | n/a | -6.8% | 8.5% |
Return vs Industry: Insufficient data to determine how 56R0 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 56R0 performed against the German Market.
Price Volatility
| 56R0 volatility | |
|---|---|
| 56R0 Average Weekly Movement | 15.1% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 56R0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 56R0's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 13 | Brian Murphy | www.nanovibronix.com |
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company’s product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation.
NanoVibronix, Inc. Fundamentals Summary
| 56R0 fundamental statistics | |
|---|---|
| Market cap | €2.53m |
| Earnings (TTM) | -€2.95m |
| Revenue (TTM) | €3.14m |
0.8x
P/S Ratio-0.9x
P/E RatioIs 56R0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 56R0 income statement (TTM) | |
|---|---|
| Revenue | US$3.29m |
| Cost of Revenue | US$1.33m |
| Gross Profit | US$1.96m |
| Other Expenses | US$5.05m |
| Earnings | -US$3.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.82 |
| Gross Margin | 59.62% |
| Net Profit Margin | -93.80% |
| Debt/Equity Ratio | 0% |
How did 56R0 perform over the long term?
See historical performance and comparison